Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

PolyOne Corporation (POL): Could New Product Launches Boost This Company’s Competitive Edge?

Page 1 of 2

The fate of the chemical industry is fundamentally tied to the financial strength of the U.S. economy. The chemical processing industry is projected to witness healthy growth backed by a noteworthy increase in the number of projects that are likely to start construction in the United States. Industrial information has recognized 231 projects worth a total investment value of more than $11 billion that have been granted the funding approval to commence construction in 2013. Although the numbers may fluctuate during the year, it exhibits a much more positive outlook for the industry as a whole than in years gone by.

Nevertheless, chemical-industry executives still confront myriad strategic challenges as they develop new formulas for growth to help them support a path to success.

PolyOne Corporation (NYSE:POL)

The point of this report is to scrutinize PolyOne Corporation (NYSE:POL) against its peers, namely LyondellBasell Industries NV (NYSE:LYB), The Dow Chemical Company (NYSE:DOW) and E I Du Pont De Nemours And Co (NYSE:DD). The companies have been picked to evaluate their overvaluation based on their P/E compared to the chemical industry, in the midst of its bright future outlook.

Financial performance analysis

Source: Morningstar

PolyOne Corporation (NYSE:POL) was among the top players to register double-digit top-line growth. Sales increased by 4.5% in fiscal 2012 and 9.2% in fiscal 2011, primarily owing to an increase of 6.9% from the acquisition of ColorMatrix and a 12% increase coming from the improved sales mix and increased market pricing linked with raw material inflation, 1.3% from foreign exchange gains, and 1.7% from acquisitions.

Nonetheless, PolyOne Corporation (NYSE:POL) lagged behind rivals Dow Chemical and du Pont in the race of net margin growth. The Dow Chemical Company (NYSE:DOW) undertook assertive actions – driving a full range of cost and cash-flow measures by launching $2.5 billion of cost-control actions. It also repaid $613 million in debt, achieved noteworthy milestones with enterprise growth projects and continuous progress towards total quality management with the focus on zero accidents, evidenced by a 36 percent improvement.

PolyOne Corporation (NYSE:POL)’s net income margin growth was at loggerheads with its peers mainly due to higher average borrowing levels in fiscal 2012, arising due to the senior secured term loan entered into on December 21, 2011, in combination with the ColorMatrix acquisition.

The net income growth from continuing operations was in fact even lower, as the company had recognized a gain on the sale of investments in SunBelt in fiscal years 2012 and 2011.

The EPS declared by PolyOne was also down at 0.8 for the same aforementioned reasons.

Current ratio portrays a corporation’s capability to pay off its liabilities as they fall due. PolyOne Corporation (NYSE:POL) is managing its working capital in an ideal manner. With a current ratio nearing 2, the company has an adequate safety margin above its legal liabilities, to absorb any volatility. Quick ratio is a more distilled measure to assess PolyOne’s liquidity position. A ratio of 1 is considered to be superlative in this industry, the case for PolyOne. Though LyondellBasell Industries NV (NYSE:LYB) has the highest current and quick ratio, it may not be an ideal situation as the corporation had too many funds tied up in its working capital, which could be put to better use. Even though E I Du Pont De Nemours And Co (NYSE:DD) has a healthy current ratio, its below-average quick ratio shows that it has its funds mainly blocked in inventory.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!